The use of corticosteroid therapy to treatment COVID-19: a bibliographic review
DOI:
https://doi.org/10.33448/rsd-v12i6.42194Keywords:
COVID-19; Treatment; Corticosteroid; Pathophysiology.Abstract
To understand the pathophysiology of the disease and understand how drug therapies can be useful in the treatment of COVID-19, reducing or not the length of hospital stay and the need for intubation in critically ill patients, especially the use of corticosteroids. This is a descriptive and qualitative narrative bibliographical review. Conducted through research platforms such as Scielo, Pubmed and Google Scholar. The initial treatment of COVID-19 is symptomatic, including analgesics and antipyretics. There is a wide range of drugs used to combat the disease, including: IFN-α, broad-spectrum antibiotics, antimalarials and antiviral drugs, among others. The use of corticosteroids is still controversial, however, in patients with viral infections they can modulate immunity and act as anti-inflammatories. Its early use in COVID-19 can be harmful, helping viral replication and interfering with the body's immune response, causing opportunistic diseases. Also, they should not be used for more than 10 days or until discharge in patients with COVID-19 pneumonia. Methylprednisolone proved to be more effective than dexamethasone in reducing mortality rates and shortening the length of stay in the ICU, however, other studies have shown it to be more effective with dexamethasone. The use of corticosteroids can be beneficial for the treatment of COVID-19, however, it is important to understand when it should be introduced into the therapeutic plan and what dose should be administered so that the benefits are greater than the risks involved with this drug.
References
Abd-Elsalam S, et al. (2021). Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study. J Med Virol. 93(10): 5833-5838. 10.1002/jmv.27122.
Alexander P. E, et al. (2021). Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents. Med Hypotheses.
Alunno A, et al. (2022). 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Ann Rheum Dis. 81(1): 34-40. 10.1136/annrheumdis-2021-221366.
Akbarialiabad H, et al. (2021). Long COVID, a comprehensive systematic scoping review. Infection. 49(6): 1163-1186. 10.1007/s15010-021-01666-x.
Aragão, J.A, et al. (2021). Ansiedade, depressão e outros transtornos mentais no estudante de medicina durante a pandemia da COVID-19. Dal Molin RS. Saúde em foco: doenças emergentes e reemergente. Guarujá: Científica Digital. 2: 15-30. https://www.downloads.editoracientifica.org/articles/210303575.pdf.
Baig A.M. (2020). Resultados deletérios no COVID-19 de longa distância: os efeitos do SARS-CoV-2 no SNC na síndrome crônica de COVID. ACS Chem Neurosci. 11 :4017–4020.
Becker R.C. (2020). COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis. 50(1): 54-67. https://onlinelibrary.wiley.com/doi/full/10.1111/jth.14768. https://doi.org/10.1007/s11239-020-02134-3.
Behera P, et al. (2020). Papel da ivermectina na prevenção da infecção por COVID-19 entre profissionais de saúde na Índia: um estudo de caso-controle combinado. medRxiv.
Brasil. Ministério da Saúde. (2020). Protocolo de manejo clínico para o novo-coronavírus (2019-nCoV). https://portalarquivos2.saude.gov.br/images/pdf/2020/fevereiro/11/protocolo-manejo-coronavirus.pdf
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral research. 178, 104787. https://doi.org/10.1016/j.antiviral.2020.104787
Castiello T, et al. (2022). COVID-19 and myocarditis: a systematic review and overview of current challenges. Heart Fail Rev. 27(1): 251-261. 10.1007/s10741-021-10087-9.
Castro, R. (2021). Vacinas contra a Covid-19: o fim da pandemia? Physis: Revista de Saúde Coletiva. 31, e310100. https://scielosp.org/article/physis/2021.v31n1/e310100/#.
Crichton M.L, et al. (2021). European Respiratory Society COVID-19 Task Force. The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline. Eur Respir Rev. 15;30(162): 210171. 10.1183/16000617.0171-2021.
Dastenae Z. H, et al. (2022). Comparison of the effect of intravenous dexamethasone and methylprednisolone on the treatment of hospitalized patients with COVID-19: a randomized clinical trial. Int J Infect. 122:659-664. 10.1016/j.ijid.2022.07.019.
Deretic V., & Timmins G. S. (2020). Azitromicina e ciprofloxacina têm um efeito semelhante à cloroquina nas células epiteliais respiratórias. bioRxiv. 10.1101/2020.03.29.008631.
Florindo H. F, et al. (2020). Abordagens imunomediadas contra COVID-19. Nat. Nanotechnol.; 15 (8):630–645.
Forte G, et al. (2020). Pandemia de COVID-19 na população italiana: validação de um questionário de transtorno de estresse pós-traumático e prevalência de sintomatologia de TEPT. Int J Environ Res Saúde Pública.; 17 :4151.
Garg D, Muthu V, Sehgal I. S, et al. (2021). Mucormicose (CAM) associada à doença por coronavírus (Covid-19): relato de caso e revisão sistemática da literatura. Micopatologia; 186 :289-298. 10.1007/s11046-021-00528-2
Gerard A, et al. (2020). Uso “off-label” de hidroxicloroquina, azitromicina, lopinavir-ritonavir e cloroquina no COVID-19: uma pesquisa de reações adversas a medicamentos cardíacas pela Rede Francesa de Centros de Farmacovigilância. Terapias; 75 (4):371–379.
Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. (2020). Manejo de covid-19 pós-agudo na atenção primária. BMJ; 370: m3026.
Griesel M, et al. (2022). Corticosteróides inalados para o tratamento de COVID-19. Cochrane Database of Systematic Reviews, Edição 3. Art. Nº: CD015125. 10.1002/14651858.CD015125.
HE X.F, et al. (2020). O treinamento microglial dependente de NLRP3 prejudicou a depuração da beta-amiloide e agravou o declínio cognitivo na doença de Alzheimer. Morte celular Dis.; 11 :849.
Hong, S., Wang, H., Zhang, Z., & Qiao, L. (2022). The roles of methylprednisolone treatment in patients with COVID-19: A systematic review and meta-analysis. Steroids, 183, 109022. https://doi.org/10.1016/j.steroids.2022.109022
Iser, B.P.M, et al. (2020). Definição de caso suspeito da COVID-19: uma revisão narrativa dos sinais e sintomas mais frequentes entre os casos confirmados. Epidemiologia e Serviços de Saúde [online]. 29(3), e2020233. <https://doi.org/10.5123/S1679-49742020000300018>. Epub 22 Jun 2020. ISSN 2237-9622.
Jiang H.J, et al. (2020). Impactos psicológicos da epidemia de COVID-19 no povo chinês: exposição, sintoma de estresse pós-traumático e regulação emocional. Asian Pac J Trop Med; 13 :252.
Jin Y, et al. (2020). Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 27;12(4):372. 10.3390/v12040372. PMID: 32230900; PMCID: PMC7232198.
John T.M, Jacob C.N, & Kontoyiannis D.P. (2021). Quando o diabetes mellitus descontrolado e o COVID-19 grave convergem: a tempestade perfeita para a mucormicose. J Fungos; 7 :298. 10.3390/jof7040298
Johns M, et al. (2021). Uma revisão das evidências de corticosteroides no COVID-19. J. Farmácia. Pratique. 0897190021998502.
Kakodkar P, et al. (2020). Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). Cureus; 12(4): 1-18. https://www.cureus.com/articles/29670-a-comprehensive-literature-review-on-the-clinical-presentation-and-management-of-the-pandemic-coronavirus-disease-2019-covid-19. https://doi.org/10.7759/cureus.7560.
Kupferschmidt K, & Cohen J. (2020). Can China's COVID-19 strategy work elsewhere? Science; 367(6482): 1061-1062.
Kounis N.G, et al. (2021). Corticosteroids for mild COVID-19 treatment: Opening the floodgates of therapeutic benefits. QJM. 10: hcab312. 10.1093/qjmed/hcab312. Epub ahead of print. PMID: 34893902; PMCID: PMC9383071.
Kuo C.H, et al. (2019). A azitromicina suprime as quimiocinas relacionadas com Th1 e Th2 IP-10/MDC na linha de células monocíticas humanas. J. Microbiol. Immunol. Infectar; 52 (6):872-879.
Leal, A.S, Paoliello, B.L, da Silva, F.B, Müller, G.M, Carvalho, I.C, Neto, J.W.S, Silva, L.F.M, da Silva, M.H, Prates, S.K.P, Peruzzo, Y.L, & Marçal, P.H.F (2022). Os diversos aspectos da imunossenescência: uma revisão sistemática / Os vários aspectos da imunossenescência: uma revisão sistemática. Brazilian Journal of Development, 8 (3), 15553–15584. https://doi.org/10.34117/bjdv8n3-006
Levi M, et al. (2020). Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol;7(6): e438-e440. https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30145-9/fulltext. https://doi.org/10.1016/S2352-3026(20)30145-9.
Li H, et al. (2020). Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents; 55(5): 105951. https://www.sciencedirect.com/science/article/abs/pii/S0924857920301011?via%3Dihub. https://doi.org/10.1016/j.ijantimicag.2020.105951.
Lier A.J, Tuan J.J, Davis M.W, et al. (2020). Relato de caso: estrongiloidíase disseminada em paciente com COVID-19. Am J Trop Med Hyg; 103 (4): 1590-1592.
Lima, C.M.A. (2020). O. Informações sobre o novo coronavírus (COVID-19). Radiologia Brasileira. 53(2): V-VI. ://www.scielo.br/scielo.php?pid=S0100-39842020000200001&script=sci_arttext&tlng=pt
Melgaço J, et al. (2020). Protective immunity after COVID-19 has been questioned: What can we do without SARS-CoV-2-IgG detection? Cell Immunol. 353: 104114. https://www.sciencedirect.com/science/article/abs/pii/S0008874920302501?via%3Dihub. https://doi.org/10.1016/j.cellimm.2020.104114.
Ministério da Saúde, Brasil. (2022). COVID-19: Painel de controle. https://covid.saude.gov.br/.
Mitra R.L, Greenstein S.A, & Epstein L.M. (2020). Um algoritmo para gerenciar o prolongamento do intervalo QT em pacientes com doença de coronavírus 2019 (COVID-19) tratados com cloroquina ou hidroxicloroquina em conjunto com azitromicina: possíveis benefícios da lidocaína intravenosa. Representante de Casos de Coração; 6 (5):244–248.
Moorthy A, Gaikwad R, Krishna S, et al. (2021). SARS-CoV-2, diabetes não controlado e corticosteróides - uma trindade profana em infecções fúngicas invasivas da região maxilofacial? Uma análise retrospectiva e multicêntrica. J Maxillofac Oral Surg. 10.1007/s12663-021-01532-1
Mouffak S, et al. (2021). Recent advances in management of COVID-19: A review. Biomed Pharmacother.143:112107. 10.1016/j.biopha.2021.112107.
Ngamprasertchai T, et al. (2021). Efficacy and Safety of Immunomodulators in Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Infect Dis Ther. 11(1): 231-248. 10.1007/s40121-021-00545-0.
Nunes, B.P, et al. (2022). Multimorbidade e população em risco para COVID-19 grave no Estudo Longitudinal da Saúde dos Idosos Brasileiros. Cadernos de Saúde Pública [online]. 36(12), e00129620. <https://doi.org/10.1590/0102-311X00129620>.
Organização Mundial de Saúde (OMS). (2021). Atualizações epidemiológicas e operacionais semanais recuperadas em 19 de julho de 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
Rehman S. U, et al. COVID-19 challenges and its therapeutics. (2021) Biomed Pharmacother. 142:112015. 10.1016/j.biopha.2021.112015.
Patel C, et al. (2022). Effect of corticosteroid therapy on mortality in COVID-19 patients-A systematic review and meta-analysis. Rev Med Virol. 32(5): e2386. 10.1002/rmv.2386.
Rodríguez-Tajes S, Miralpeix A, Costa J, et al. (2021). Baixo risco de reativação da hepatite B em pacientes com COVID-19 grave que recebem terapia imunossupressora. J Hepatite Viral. 28 (1):89–94.
Shereen, M.A, et al. (2020). COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses, Journal of Advanced Research, 24:91-98, ISSN 2090-1232, https://doi.org/10.1016/j.jare.2020.03.005. (https://www.sciencedirect.com/science/article/pii/S2090123220300540)
Teixeira, L.A.C, et al. (2021). Brazilian medical students’mental health during coronavirus disease 2019 pandemic. Jornal Brasileiro de Psiquiatria. 70: 21-29. https://www.scielo.br/j/jbpsiq/a/yjxwLdpJ6q5CJJCpPNxKr5R/.
Tenforde M.W, et al. (2020). Duração dos sintomas e fatores de risco para retorno tardio à saúde habitual entre pacientes ambulatoriais com COVID-19 em uma rede multiestadual de sistemas de saúde - Estados Unidos, março-junho de 2020. MMWR Morb Mortal Wkly Rep; 69 (30): 993-8.
Tham S.M, Lim W.Y, Lee C.K, et al. (2020). Quatro pacientes com COVID-19 e tuberculose, Cingapura, abril a maio de 2020. Emerg Infect Dis. 26 (11):2764–2766.
To, K.K, et al. (2021). Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerging microbes & infections. 10(1): 507-535. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006950/.
Valverde, A.J, et al. (2021). Covid-19: fisiopatologia, história natural e diagnóstico. Rev Eug Esp, Riobamba, 15(2): 98-114. <http://scielo.senescyt.gob.ec/scielo.php?script=sci_arttext&pid=S2661-67422021000200098&lng=es&nrm=iso>.
Van K.S, Olde Hartman T.C, Lucassen P.L.B.J, & Van Jaarsveld C.H.M. (2022). Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract. 19;39(1):159-167. 10.1093/fampra/cmab076.
Vigilância V. (2020). As características epidemiológicas de um surto de 2019 novas doenças de coronavírus (COVID-19). China CDC Wkly. 2 (8):113-122.
World Health Organization (WHO). (2020). Director-General's opening remarks at the media briefing on COVID-19-11 March 2020. Geneva: WHO. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19
Wu F, et al. (2020). Neutralizando as respostas de anticorpos ao SARS-CoV-2 em uma coorte de pacientes recuperados de COVID-19 e suas implicações. medRxiv. 9 :199. 10.1101/2020.03.30.20047365.
Yang J, et al. (2020). Prevalência de comorbidades no novo coronavírus Wuhan (COVID-19) infecção: uma revisão sistemática e meta-análise. Int. J. Infectar; 94 :91-95.
Yang X, et al. (2020). Curso clínico e resultados de pacientes críticos com Pneumonia por SARS-CoV-2 em Wuhan, China: um estudo observacional, retrospectivo e centrado em um único. Lancet Respir. Med.; 8 (5):475–481.
Yuki K, et al. (2020). COVID-19 pathophysiology: A review. Clin Immunol. 215: 1-7. https://www.sciencedirect.com/science/article/abs/pii/S152166162030262X?via%3Dihub. https://doi.org/10.1016/j.clim.2020.108427.
Zaim S, Chong J.H, Sankarnarayanan V, & Harky A. (2020). COVID-19 e resposta multiorgânica. Curr Probl Cardiol; 45 (8): 100618.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Isabela Saito Moreira; Nathalia Araújo de Macedo; Daniel Dias Santos Feres
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
